Advertisement

Topics

Efficacy of Granulocyte-Colony Stimulating Factor (G-CSF)

2018-04-20 09:47:10 | BioPortfolio

Published on BioPortfolio: 2018-04-20T09:47:10-0400

Clinical Trials [141 Associated Clinical Trials listed on BioPortfolio]

A Clinical Trial of Patients With Solid Tumours Receiving Granulocyte Colony Stimulating Factor as Primary Prophylaxis for Chemotherapy-induced Neutropenia, in a Docetaxel Based Regimen

Primary Objective: To evaluate the incidence and severity of neutropenia in patients being treated for solid tumours with a Taxotere® based regimen when Granocyte® 34 is being used as a...

Management of Severe Chemotherapy-induced Neutropenia in Advanced Breast Cancer

This study will assess treatment of febrile neutropenia in subjects in with relapsing or metastatic breast cancer whose risk level for febrile neutropenia is low and who are receiving seco...

ANF-Rho in the Treatment of Chronic Neutropenia

A 6 month safety, tolerability, efficacy and pharmacokinetic study with ANF-Rho to treat patients with chronic neutropenia.

Screening for Genes in Patients With Congenital Neutropenia

Syndromic congenital neutropenia (SCN) includes a heterogeneous group of diseases characterized by congenital neutropenia associated with the involvement of other organs. Most patients hav...

Incidence of Febrile Neutropenia

Prospective observational study of febrile neutropenia (FN) and pegfilgrastim primary prophylaxis in breast cancer and non-Hodgkin's lymphoma patients receiving high (>20%) FN-risk chemoth...

PubMed Articles [116 Associated PubMed Articles listed on BioPortfolio]

Prophylaxis of Chemotherapy-induced Neutropenia and Febrile Neutropenia with Lipegfilgrastim in Patients with Non-Hodgkin Lymphoma (NADIR study).

The prospective non-interventional study (NIS) NADIR was designed to evaluate both effectiveness and safety of prophylactic use of lipegfilgrastim (Lonquex ), a glycopegylated granulocyte colony stimu...

Prophylaxis of chemotherapy-induced neutropenia and febrile neutropenia with lipegfilgrastim in 2489 cancer patients: final results from the non-interventional study NADIR.

The non-interventional study (NIS) NADIR (DRKS00005711) evaluated the effectiveness and safety of prophylaxis with lipegfilgrastim, a glycopegylated granulocyte-colony stimulating factor, in 2500 pati...

Epidemiology and source of infection in patients with febrile neutropenia: A ten-year longitudinal study.

No recent studies are available from Saudi Arabia on the etiology of febrile neutropenia. The objective of this study was to describe the characteristics of patients with febrile neutropenia and to ca...

Early discontinuation of antibiotics for febrile neutropenia versus continuation until neutropenia resolution in people with cancer.

People with cancer with febrile neutropenia are at risk of severe infections and mortality and are thus treated empirically with broad-spectrum antibiotic therapy. However, the recommended duration of...

Two cases of tacrolimus-induced neutropenia: A probably under-diagnosed cause of neutropenia after solid-organ transplantation.

Medical and Biotech [MESH] Definitions

A hematopoietic growth factor which promotes proliferation and maturation of neutrophil granulocytes. Clinically it is effective in decreasing the incidence of febrile neutropenia in patients with non-myeloid malignancies receiving myelosuppressive therapy or in reducing the duration of neutropenia and neutropenia-related clinical sequelae in patients with non-myeloid malignancies undergoing myeloblastive chemotherapy followed by BMT. It has also been used in AIDS patients with CMV retinitis being treated with GANCICLOVIR. (Gelman CR, Rumack BH & Hess AJ (eds): DRUGDEX(R) System. MICROMEDEX, Inc., Englewood, Colorado (Edition expires 11/30/95))

A decrease in the number of neutrophilic leukocytes in the blood. (Dorland, 27th ed)

Fever accompanied by a significant reduction in the number of NEUTROPHILS.

A rare complication of rheumatoid arthritis with autoimmune NEUTROPENIA; and SPLENOMEGALY.

FEVER accompanied by a significant reduction in NEUTROPHIL count associated with CHEMOTHERAPY.

More From BioPortfolio on "Efficacy of Granulocyte-Colony Stimulating Factor (G-CSF)"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial